Publication | Closed Access
E5531, a Pure Endotoxin Antagonist of High Potency
321
Citations
20
References
1995
Year
PharmacotherapyViable Escherichia ColiDrug ResistanceInflammationMolecular PharmacologyPure Endotoxin AntagonistAntimicrobial ResistanceHealth SciencesMechanism Of ActionAntibacterial AgentAntimicrobial CompoundPharmacologyClinical MicrobiologyPhagocyteGram-negative Bacterial SepsisEndotoxin Antagonist E5531MicrobiologyMedicineDrug Discovery
Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.
| Year | Citations | |
|---|---|---|
Page 1
Page 1